Breakfast breakthrough? study tests if food can improve kidney cancer drug tolerability

NCT ID NCT05263245

Completed Disease control Sponsor: dr. Tom van der Hulle Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looked at whether taking the kidney cancer drug cabozantinib with a light breakfast changes how much drug gets into the body. Twelve patients with advanced kidney cancer took the drug both on an empty stomach and with a light breakfast, and researchers measured drug levels in their blood. The goal is to see if eating a light breakfast could allow patients to skip doses occasionally, potentially reducing side effects and costs.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cabozantinib
What this could lead to: If it works, this could lead to a more convenient dosing schedule for cabozantinib, potentially reducing side effects and treatment costs.
What could go wrong: This is a small, early-phase study with only 12 participants, so results may not apply broadly. The main goal is measuring drug levels, not proving better outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

carcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RENAL CELL CARCINOMA

Contacts and locations

Locations

Erasmus Medical Center

Rotterdam, South Holland, 3015 GD, Netherlands
Leids Universitair Medisch Centrum

Leiden, South Holland, 2333 ZA, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.